GlassScriptPhysician profile
Nisheet Prasad
NPI 1144258856
$7,083.69
in general payments reported to CMS, 2019-2025
31 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $184 · 2021: $561 · 2022: $914 · 2023: $1,699 · 2024: $1,580 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,750 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,749.55 |
| Education | $203.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,994.61 | 2019-2025 | |
| Amgen INC. | $1,017.67 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $885.87 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Glaxosmithkline, LLC. | $758.54 | 2019-2025 | Benlysta, Nucala |
| Amneal Pharmaceuticals LLC | $574.87 | 2019-2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $411.82 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $247.78 | 2019-2023 | |
| Lilly USA, LLC | $201.61 | 2019-2024 | Taltz |
| Horizon Therapeutics Plc | $193.78 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $100.52 | 2025 | Monoferric |
| Pfizer INC. | $85.36 | 2021-2023 | |
| Aurinia Pharma U.S., INC. | $76.55 | 2021-2023 | Lupkynis |
| Xeris Pharmaceuticals, INC. | $54.31 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.70 | 2021-2023 | Jardiance |
| Abbott Laboratories | $47.27 | 2022-2023 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $43.47 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $36.44 | 2020-2021 | |
| Medtronic, INC. | $31.42 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $30.80 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $30.08 | 2019-2024 | Actemra |
| Hikma Pharmaceuticals USA | $26.95 | 2021 | |
| Novo Nordisk INC | $25.16 | 2021-2022 | |
| Mannkind Corporation | $24.07 | 2021 | |
| Genzyme Corporation | $21.48 | 2024 | |
| Depuy Synthes Sales INC. | $18.31 | 2023 | Orthovisc, Monovisc |
| Sandoz INC. | $17.74 | 2023 | Hyrimoz |
| Ucb, INC. | $16.76 | 2022 | |
| Organon LLC | $15.36 | 2023 | Hadlima, Renflexis |
| Sobi, INC | $14.76 | 2022 | |
| Embecta Corp. | $13.79 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ultragenyx Pharmaceutical INC. | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisheet Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.